Skip to main content
SpringerLink
Log in

Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents

  • Chapter
  • First Online:
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 1449 Accesses

Abstract

Antibody drug conjugates (ADCs) have begun to have a tremendous impact on the treatment of cancer and other pathological conditions. A current limitation in ADC development is that much effort and time is needed to fully optimise the combination of antibody, linker and drug. New linker strategies are required to ensure that more homogeneous and stable ADCs can be produced with more predictable in vivo behaviour without the need for extensive re-optimisation, especially if one component of the ADC is changed. In order to improve both the homogeneity and the stability of ADCs, we have developed linkers that allow site-specific drug conjugation based on bis-sulphones that covalently re-bridge reduced disulphide bonds. The bis-sulphone reagents comprise a drug, a linker and a bis-reactive conjugating moiety that is capable of undergoing reaction with both sulphur atoms derived from a reduced disulphide bond in antibodies and antibody fragments. We have demonstrated that the bis-sulphone-derived conjugates retain antigen-binding, are stable in serum and exhibit potent and antigen-selective cell killing in both in vitro and in vivo cancer models. Disulphide re-bridging conjugation is a general approach to prepare stable ADCs, which does not require the antibody to be recombinantly re-engineered for site-specific conjugation. The bis-sulphone linker-platform is being developed by Abzena plc under the trade name ThioBridge™.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agarwal P, Bertozzi CR (2015) Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem 26(2):176–192

    Article  CAS  PubMed  Google Scholar 

  • Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, Senter PD (2008) Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19(3):759–765

    Article  CAS  PubMed  Google Scholar 

  • Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A 109(40):16101–16106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Badescu G, Bryant P, Bird M, Henseleit K, Swierkosz J, Parekh V, Tommasi R, Pawlisz E, Jurlewicz K, Farys M, Camper N, Sheng X, Fisher M, Grygorash R, Kyle A, Abhilash A, Frigerio M, Edwards J, Godwin A (2014) Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug Chem 25(6):1124–1136

    Article  CAS  PubMed  Google Scholar 

  • Balan S, Choi J, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S (2007) Site-specific PEGylation of protein disulfide bonds using a three carbon bridge. Bioconjug Chem 18(1):61–76

    Article  CAS  PubMed  Google Scholar 

  • Beck A (2014) Review of antibody-drug conjugates, methods in molecular biology series: a book edited by Laurent Ducry. MAbs 6(1):30–33

    Article  Google Scholar 

  • Behrens CR, Liu B (2014) Methods for site-specific drug conjugation to antibodies. MAbs 6(1):46–53

    Article  PubMed  Google Scholar 

  • Betz SF (1993) Disulfide bonds and the stability of globular proteins. Protein Sci 2:1551–1558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brocchini S, Balan S, Godwin A, Choi J, Zloh M, Shaunak S (2006) PEGylation of native disulfide bonds in proteins. Nat Protoc 1(5):2241–2252

    Article  CAS  PubMed  Google Scholar 

  • Brocchini S, Godwin A, Balan S, Choi J, Zloh M, Shaunak S (2008) Disulfide bridged based PEGylation of proteins. Adv Drug Deliv Rev 60(1):3–12

    Article  CAS  PubMed  Google Scholar 

  • Bryant P, Pabst M, Badescu G, Bird M, McDowell W, Jamieson E, Swierkosz J, Jurlewicz K, Tommasi R, Henseleit K, Sheng X, Camper N, Manin A, Kozakowska K, Peciak K, Laurine E, Grygorash R, Kyle A, Morris D, Parekh V, Abhilash A, Choi JW, Edwards J, Frigerio M, Baker MP, Godwin A (2015) In vitro and in vivo evaluation of cysteine rebridged trastuzumab-MMAE antibody drug conjugates with defined drug-to-antibody ratios. Mol Pharm 12(6):1872–1879

    Article  CAS  PubMed  Google Scholar 

  • Bryden F, Maruani A, Savoie H, Chudasama V, Smith ME, Caddick S, Boyle RW (2014) Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment. Bioconjug Chem 25(3):611–617

    Article  CAS  PubMed  Google Scholar 

  • Castaneda L, Maruani A, Schumacher FF, Miranda E, Chudasama V, Chester KA, Baker JR, Smith ME, Caddick S (2013) Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation. Chem Commun (Camb) 49(74):8187–8189

    Article  CAS  Google Scholar 

  • Chari RV, Miller ML, Widdison WC (2014) Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem 53(15):3796–3827

    Article  CAS  Google Scholar 

  • Choi J, Godwin A, Balan S, Bryant P, Cong Y, Pawlisz E, Porssa M, Rumpf N, Singh R, Powell K, Brocchini S (2009) Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation. In: Veronese FM (ed) Protein PEGylation, basic science and biological applications. Springer, Basel, pp 47–74

    Chapter  Google Scholar 

  • Chudasama V, Smith ME, Schumacher FF, Papaioannou D, Waksman G, Baker JR, Caddick S (2011) Bromopyridazinedione-mediated protein and peptide bioconjugation. Chem Commun (Camb) 47(31):8781–8783

    Article  CAS  Google Scholar 

  • Cline DJ, Redding SE, Brohawn SG, Psathas JN, Schneider JP, Thorpe C (2004) New water-soluble phosphines as reductants of peptide and protein disulfide bonds: reactivity and membrane permeability. Biochemistry 43(48):15195–15203

    Article  CAS  PubMed  Google Scholar 

  • Darby N, Creighton TE (1995) Disulfide bonds in protein folding and stability. Methods Mol Biol 40:219–252

    CAS  PubMed  Google Scholar 

  • Darby N, Creighton TE (1997) Probing protein folding and stability using disulfide bonds. Mol Biotechnol 7(1):57–77

    Article  CAS  PubMed  Google Scholar 

  • Debaene F, Boeuf A, Wagner-Rousset E, Colas O, Ayoub D, Corvaia N, Van Dorsselaer A, Beck A, Cianferani S (2014) Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment. Anal Chem 86(21):10674–10683

    Article  CAS  PubMed  Google Scholar 

  • del Rosario RB, Wahl RL, Brocchini SJ, Lawton RG, Smith RH (1990) Sulfhydryl site-specific cross-linking and labeling of monoclonal antibodies by a fluorescent equilibrium transfer alkylation cross-link reagent. Bioconjug Chem 1(1):51–59

    Article  PubMed  Google Scholar 

  • Dennler P, Chiotellis A, Fischer E, Bregeon D, Belmant C, Gauthier L, Lhospice F, Romagne F, Schibli R (2014) Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem 25(3):569–578

    Article  CAS  PubMed  Google Scholar 

  • Dokter W, Ubnik R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van der Dobbelsteen D, Egging D, Mattaar E, Groothius P, Beusker P, Coumans R, Elgersma R, Menge W, Joosten J, Spijker H, Huijbregts T, de Groot V, Eppink M, de Roo G, Verheijden G, Timmers M (2014) Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther 13(11):2618–2629

    Article  CAS  PubMed  Google Scholar 

  • Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17(1):114–124

    Article  CAS  PubMed  Google Scholar 

  • Fass D (2012) Disulfide bonding in protein biophysics. Annu Rev Biophys 41:63–79

    Article  CAS  PubMed  Google Scholar 

  • Flemming A (2014) Antibody engineering: fine-tuning antibody-drug conjugates. Nat Rev Drug Discov 13(3):178

    Article  CAS  PubMed  Google Scholar 

  • Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4):1458–1465

    Article  CAS  PubMed  Google Scholar 

  • Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P (2013) Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists antibody-drug conjugate working group position paper. Bioanalysis 5(9):997–1006

    Article  CAS  PubMed  Google Scholar 

  • Hallam TJ, Smider VV (2014) Unnatural amino acids in novel antibody conjugates. Future Med Chem 6(11):1309–1324

    Article  CAS  PubMed  Google Scholar 

  • Hallam TJ, Wold E, Wahl A, Smider VV (2015) Antibody conjugates with unnatural amino acids. Mol Pharm 12(6):1848–1862

    Article  CAS  PubMed  Google Scholar 

  • Hamblett KJ, Mayer DL, Chace DF, Zabinsky RF, Cerveny CG, Sun MM, Senter PD, Francisco JA (2004a) Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate. Proc Am Assoc Cancer Res 45:624

    Google Scholar 

  • Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004b) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063–7070

    Google Scholar 

  • Han JC, Han GY (1994) A procedure for quantitative determination of tris(2-carboxyethyl)phosphine, an odorless reducing agent more stable and effective than dithiothreitol. Anal Biochem 220(1):5–10

    Article  CAS  PubMed  Google Scholar 

  • Hogg PJ (2003) Disulfide bonds as switches for protein function. Trends Biochem Sci 28(4):210–214

    Article  CAS  PubMed  Google Scholar 

  • http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002455/WC500135054.pdf (2012) EMA Assessment report: Adcetris

  • Jeger S, Zimmermann K, Blanc A, Grünberg J, Honer M, Hunziker P, Struthers H, Schibli R (2010) Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed 49:9995–9997

    Article  CAS  Google Scholar 

  • Jones MW, Strickland RA, Schumacher FF, Caddick S, Baker JR, Gibson MI, Haddleton DM (2012) Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents. J Am Chem Soc 134(3):1847–1852

    Article  CAS  PubMed  Google Scholar 

  • Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Wong WL, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932

    Article  CAS  PubMed  Google Scholar 

  • Khalili H, Godwin A, Choi J, Lever R, Khaw PT, Brocchini S (2012) Comparative binding of disulfide-bridged PEG-Fabs. Bioconjug Chem 23(11):2262–2277

    Article  CAS  PubMed  Google Scholar 

  • Khalili H, Godwin A, Choi J, Lever R, Brocchini S (2013) Fab-PEG-fab as a potential antibody mimetic. Bioconjug Chem 24(11):1870–1882

    Article  CAS  PubMed  Google Scholar 

  • Liberatore FA, Comeau RD, McKearin JM, Pearson DA, Belonga BQ 3rd, Brocchini SJ, Kath J, Phillips T, Oswell K, Lawton RG (1990) Site-directed chemical modification and cross-linking of a monoclonal antibody using equilibrium transfer alkylating cross-link reagents. Bioconjug Chem 1(1):36–50

    Article  CAS  PubMed  Google Scholar 

  • Liu H, May, K. (2012) DIsulfide bond structures of IgG molecules, structural variantions, chemical modifications and possible impacts to stability and biological function. MAbs 4(1):17–23

    Google Scholar 

  • Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH (2010) Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem 82(12):5219–5226

    Article  CAS  PubMed  Google Scholar 

  • Mack F, Ritchie M, Sapra P (2014) The next generation of antibody drug conjugates. Semin Oncol 41(5):637–652

    Article  CAS  PubMed  Google Scholar 

  • Marcoux J, Champion T, Colas O, Wagner-Rousset E, Corvaia N, Van Dorsselaer A, Beck A, Cianferani S (2015) Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Protein Sci 24(8):1210–1223

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marculescu C, Kossen H, Morgan RE, Mayer P, Fletcher SA, Tolner B, Chester KA, Jones LH, Baker JR (2014) Aryloxymaleimides for cysteine modification, disulfide bridging and the dual functionalization of disulfide bonds. Chem Commun (Camb) 50(54):7139–7142

    Article  CAS  Google Scholar 

  • Maruani A, Smith MEB, Miranda E, Chester KA, Chudasama V, Caddick S (2015) A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat Commun 6:6645

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miao Z, Hong Y, Zhu T, Chucholowski AW (2013) Drug-conjugates, conjugation methods, and uses thereof. Google Patents

    Google Scholar 

  • Narayan M (2012) Disulfide bonds: protein folding and subcellular protein trafficking. FEBS J 279(13):2272–2282

    Article  CAS  PubMed  Google Scholar 

  • Nelson AL (2012) Antibody fragments: hope and hype. MAbs 2(1):77–83

    Article  Google Scholar 

  • Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Site-specific antibody drug conjugates for cancer therapy. MAbs 6(1):34–45

    Article  PubMed  Google Scholar 

  • Powers G, Hudson PJ, Wheatcroft MP 2012 Design and production of multimeric antibody fragments, focused on diabodieswith enhanced clinical efficacy. Antibody Engineering. Chapter 39

    Google Scholar 

  • Rohrer T (2012) Consideration for the safe and effective manufacturing of antibody drug conjugates. Chimica Oggi-Chemistry Today 30(5):76–79

    CAS  Google Scholar 

  • Ryan CP, Smith ME, Schumacher FF, Grohmann D, Papaioannou D, Waksman G, Werner F, Baker JR, Caddick S (2011) Tunable reagents for multi-functional bioconjugation: reversible or permanent chemical modification of proteins and peptides by control of maleimide hydrolysis. Chem Commun (Camb) 47(19):5452–5454

    Article  CAS  Google Scholar 

  • Schumacher FF, Nobles M, Ryan CP, Smith ME, Tinker A, Caddick S, Baker JR (2011) In situ maleimide bridging of disulfides and a new approach to protein PEGylation. Bioconjug Chem 22(2):132–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schumacher F, Sanchania VA, Tolner B, Wright ZVF, Ryan CP, Smith MEB, Ward JM, Caddick S, Kay CWM, Aeppli G, Chester KA, Baker JR (2013) Homogeneous antibody fragment conjugation by disulfide bridging introduces ‘spinostics’. Sci Rep 3:1525–1532

    Article  PubMed  PubMed Central  Google Scholar 

  • Schumacher FF, Nunes JPM, Maruani A, Chudasama V, Smith MEB, Chester KA, Baker JR, Caddick S (2014) Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. Org Biomol Chem 12:7261–7269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13(3):235–244

    Article  CAS  PubMed  Google Scholar 

  • Shaunak S, Godwin A, Choi J, Balan S, Pedone E, Vijayarangam D, Heidelberger S, Teo I, Zloh M, Brocchini S (2006) Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol 2(6):312–313

    Article  CAS  PubMed  Google Scholar 

  • Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30(2):184–189

    Article  CAS  PubMed  Google Scholar 

  • Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15–29

    Article  CAS  PubMed  Google Scholar 

  • Smith MEB, Schumacher FF, Ryan CP, Tedaldi LM, Papaioannou D, Waksman G, Caddick S, Baker JR (2010) Protein modification, bioconjugation, and disulfide bridging using bromomaleimides. J Am Chem Soc 132(6):1960–1965

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sochaj AM, Swiderska KW, Otlewski J (2015) Current methods for the synthesis of homogeneous antibody-drug conjugates. Biotechnol Adv. doi:10.1016/j.biotechadv.2015.05.001

    PubMed  Google Scholar 

  • Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, Ho WH, Farias S, Casas MG, Abdiche Y, Zhou D, Chandrasekaran R, Samain C, Loo C, Rossi A, Rickert M, Krimm S, Wong T, Chin SM, Yu J, Dilley J, Chaparro-Riggers J, Filzen GF, O’Donnell CJ, Wang F, Myers JS, Pons J, Shelton DL, Rajpal A (2013) Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 20(2):161–167

    Article  CAS  PubMed  Google Scholar 

  • Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, Casas MG, Dorywalska M, Farias S, Pios A, Lui V, Dushin R, Zhou D, Navaratnam T, Tran TT, Sutton J, Lindquist KC, Han B, Liu SH, Shelton DL, Pons J, Rajpal A (2015) Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33(7):694–696

    Article  CAS  PubMed  Google Scholar 

  • Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, Alley SC (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16(5):1282–1290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song F, DeGuzman MJ, Ensari S, Pinkstaff JK, Sullivan LM, Biroc SL, Cho H, Schultz PG, DiJoseph J, Dougher M, Ma D, Dushin R, Leal M, Tchistiakova L, Feyfant E, Gerber HP, Sapra P (2014) A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A 111(5):1766–1771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Trail PA (2013) Antibody drug conjugates as cancer therapeutics. Antibodies 2:113–129

    Article  CAS  Google Scholar 

  • Trivedi MV, Laurence JS, Siahaan TJ (2009) The role of thiols and disulfides on protein stability. Curr Protein Pept Sci 10(6):614–625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vidarsson G, Dekkers G, Rispens T (2014) IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5:520

    Article  PubMed  PubMed Central  Google Scholar 

  • Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB (2001) Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Int J Cancer 93(4):590–600

    Article  CAS  PubMed  Google Scholar 

  • Wakankar A, Chen Y, Gokarn Y, Jacobson FS (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 3(2):161–172

    Article  PubMed  PubMed Central  Google Scholar 

  • Wedemeyer WJ, Welker E, Narayan M, Scheraga HA (2000) Disulfide bonds and protein folding. Biochemistry 39(15):4207–4216

    Article  CAS  PubMed  Google Scholar 

  • Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA (1993) (6-maleimidocaproyl)hydrazone of doxorubicin – a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 4(6):521–527

    Article  CAS  PubMed  Google Scholar 

  • Wong SS (1991) Chemistry of protein conjugation and cross-linking. CRC Press, Boca Raton, FL, p 340

    Google Scholar 

  • www.ClinicalTrials.gov

  • Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812–1821

    Article  CAS  PubMed  Google Scholar 

  • Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, Tran C, Uter NT, Yin G, Rivers PJ, Yam AY, Wang WD, Steiner AR, Bajad SU, Penta K, Yang W, Hallam TJ, Thanos CD, Sato AK (2014) Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem 25(2):351–361

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We sincerely thank our Abzena colleagues, past and present, for their contributions to the development of the technology described. We also thank ImaginAb Inc. for kind use of Fig. 3.10. Contact: martin.pabst@abzena.com or mark.frigerio@abzena.com

Author information

Authors and Affiliations

  1. Abzena plc, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, UK

    Martin Pabst, Matthew Bird, Mark Frigerio & Antony Godwin

Authors
  1. Martin Pabst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Bird
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Frigerio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antony Godwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Martin Pabst or Mark Frigerio .

Editor information

Editors and Affiliations

  1. NBE-Therapeutics Ltd., Basel, Switzerland

    Ulf Grawunder

  2. Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

    Stefan Barth

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Pabst, M., Bird, M., Frigerio, M., Godwin, A. (2017). Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents. In: Grawunder, U., Barth, S. (eds) Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins. Milestones in Drug Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-46877-8_3

Download citation

Publish with us

Policies and ethics

Search

Navigation